Recent Updates — ALGN
The Board of Directors appointed Jennifer L. Davis, former CEO of Procter & Gamble’s Global Healthcare business, as Chief Executive Officer-elect and a member of the Board, effective November 2, 2026. She will assume the role of President and CEO on December 31, 2026, succeeding Joseph M. Hogan, who will retire from executive duties but remain as a strategic advisor until June 2027. The Board increased its size to eleven directors to accommodate Davis’s appointment. Her compensation package includes a $1.3 million base salary, a $2 million signing bonus, and equity awards valued at $16.5 million. Align Technology designs and manufactures the Invisalign clear aligner system and related digital dentistry technologies.
Align Technology reported third-quarter 2026 total revenues of $1.015 billion, a 1.9% increase year-over-year, driven by a 4.2% rise in Clear Aligner revenue to $839.3 million and a 6.6% increase in case volume to 690.6 thousand. Diluted net income per share reached $1.90 on GAAP basis and $2.80 on non-GAAP basis, reflecting improved profitability with an operating margin of 16.7%. The company also announced plans to repurchase up to $300 million of common stock in the fourth quarter. Align Technology designs, manufactures, and sells clear aligners, intraoral scanners, and CAD/CAM software for digital orthodontics.
Align Technology appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors effective August 27, 2026, increasing board size from ten to eleven members. Concurrently, Andrea L. Saia resigned as a director effective September 23, 2026, following thirteen years of service, prompting the board size to revert to ten directors. Neither departure was due to disagreements with company operations or policies. Align Technology is a medical device company that designs and manufactures clear aligners, intraoral scanners, and CAD/CAM software for digital orthodontics.
Align Technology announced strategic initiatives following discussions with Elliott Investment Management, including the appointment of three new independent directors to its Board of Directors with expertise in healthcare technology and global operations. The company engaged a leading consulting firm to conduct a comprehensive review aimed at enhancing commercial execution, margin expansion, and earnings growth. Additionally, Align increased its 2026 share repurchase commitment to $400 million–$500 million, reflecting management's confidence in the company's long-term value. These actions are intended to support sustainable revenue growth and capitalize on market opportunities in digital orthodontics and restorative dentistry.
Align Technology reported second quarter 2026 financial results with total revenues of $1.06 billion, a 4.3% year-over-year increase driven by record Clear Aligner shipments of 691.8 thousand cases and an 8.2% rise in segment revenue to $870.9 million. Non-GAAP diluted net income per share was $2.64, while GAAP results included a $37.5 million liability for UK VAT. The company announced fiscal 2026 full-year revenue growth guidance of 3% to 4%, with Clear Aligner volume expected to grow approximately 6%. Management also raised the 2026 stock repurchase target to $400–$500 million and provided preliminary outlook for fiscal 2027 operating margin expansion. Align Technology is a medical device company that designs, manufactures, and sells clear aligners, intraoral scanners, and CAD/CAM software for digital orthodontics.
Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer, resigned from Align Technology, Inc. effective August 1, 202key. Align Technology, Inc. operates in the medical device industry, providing clear aligner technology and clear aligner systems.